About this trial
Muscle cramps are common in patients with liver disease and associated with significantly diminished quality of life. Patients with cirrhosis often experience muscle cramps with varied frequency and severity. The exact mechanisms by which they occur remain unclear, although a number of pathophysiological events unique to liver disease may contribute. Clinical studies have identified alterations in 3 areas: nerve function, energy metabolism, and plasma volume/electrolytes (1) Orphenadrine is an anticholinergic drug with prominent central nervous system (CNS) and peripheral actions used to treat painful muscle spasms and other similar conditions. The combination of anticholinergic effects and CNS penetration make orphenadrine useful for pain of all etiologies, including from: radiculopathy, muscles, and headaches. \[3,4\]
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Cirrhosis
Muscle cramps( ≥3 cramps per week )
Disqualifiers
• Allergy to orphenadrine
Renal impairment
Pregnant and lactating women
Peripheral vascular disease
Trial design
Parallel
Treatments tested in this trial
orphenadrine
DrugOrphenadrine in muscle cramps in cirrhotic patients
Placebo
Drugcalcium in muscle cramps in cirrhotic patients
Treatment groups
Trial outcomes
Primary outcomes
Frequency of muscle cramps
questionnaire
Secondary outcomes
Quality of life of these patients
questionnaire
Sponsors and contacts
Click on the lead sponsor to view all of their trials.